Andere talen Hanall Biopharma Co., Ltd.

Aandelen

A009420

KR7009420001

slotkoers Korea S.E. Andere beurzen 00:00:00 03-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
33.150 ^KRW	+5,07%		-3,63%	-25,17%

14/05	Hanall Biopharma Co, Ltd. Rapporteert winstresultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI
03/05	HanAll Biopharma kondigt de start aan van de fase III gerandomiseerde, dubbel gemaskeerde voertuiggecontroleerde VELOS-4-studie waarbij Tanfanercept wordt geëvalueerd voor de behandeling van droge-ogenaandoeningen	CI

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

HanAll Biopharma Signs Licensing Agreement with Turn Biotechnologies to Develop Novel Treatments for Eye and Ear Diseases	29/05
Turn Biotechnologies Signs Global Licensing Agreement with HanAll Biopharma to Develop Eye and Ear Therapies	28/05
Hanall Biopharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease	03/05
Hanall Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	06/03
Vincere Biosciences announces strategic investment from Daewoong Pharmaceutical and HanAll Biopharma to foster collaboration	13-06-23
HanAll Biopharma and Daewoong Pharmaceutical Co-invest in Vincere Biosciences for Collaborative Opportunities in Parkinson's disease	13-06-23
Vincere Biosciences Inc announced that it has received funding from Hanall Biopharma Co., Ltd., Daewoong pharmaceutical Co.,Ltd	12-06-23
Hanall Biopharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15-05-23
HanAll Biopharma Reports First Quarter 2023 Results and Provides Business Update	01-05-23
HanAll Biopharma Assigns Su-jin Park as Co-CEO to Drive Next Phase of Growth	30-03-23
HanAll Biopharma Opens Applications for the 2023 Pharmaceutical Industry Fellowship Program	16-03-23
HanAll Biopharma Invests in Interon to Seek Collaboration Opportunities	13-02-23
Interon Laboratories, Inc. announced that it has received funding from Hanall Biopharma Co., Ltd.	13-02-23
Interon Laboratories, Inc. announced that it expects to receive funding from Hanall Biopharma Co., Ltd.	10-02-23
Immune Thrombocytopenia Pipeline as Novel and Extensive 30+ Therapies Likely to Enter in the Treatment Domain	09-12-22
HanAll Biopharma Reports Third Quarter 2022 Results and Provides Business Update	16-11-22
HanAll Biopharma's Licensed Partner in China Provides Updates on Phase 3 Trial in Dry Eye Disease in China	11-10-22
HanAll's Licensed Partner in China Enters Sublicense Agreement with CSPC to Further Accelerate Development of Batoclimab	11-10-22
Hanall's Second FcRn Inhibitor HL161ANS to Be Added to the Development Program of Its Licensed Partner	04-10-22

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Hanall Biopharma Co., Ltd.

Aandelen

A009420

KR7009420001

Andere talen

Filters